LifeSci Capital analyst Rami Katkhuda maintained a Buy rating on MoonLake Immunotherapeutics (MLTX – Research Report) today and set a price target of $75.00.
Rami Katkhuda has given his Buy rating due to a combination of factors surrounding MoonLake Immunotherapeutics. The company is advancing its Phase III VELA program, which is evaluating the efficacy of sonelokimab in treating moderate-to-severe hidradenitis suppurativa (HS). This program is on track for a pivotal readout by mid-2025, and the protocol closely mirrors the successful Phase II MIRA study, which adds confidence to the potential outcomes.
Additionally, IL-17A/F inhibitors, such as sonelokimab, are perceived by key opinion leaders as offering a favorable risk/benefit profile compared to other treatment options for HS. This positions MoonLake’s therapeutic approach as potentially more effective, especially when considering the limitations seen in recent competitor results. These strategic and clinical factors contribute to the positive outlook for MoonLake’s stock.
Katkhuda covers the Healthcare sector, focusing on stocks such as Mineralys Therapeutics, Inc., VYNE Therapeutics, and Viridian Therapeutics. According to TipRanks, Katkhuda has an average return of 19.9% and a 44.23% success rate on recommended stocks.